dr riess on treatment developments in alk and ros1 nsclc
Published 1 month ago • 57 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
1:51
dr. riess on ros1 fusions in lung cancer
-
3:55
treatment considerations in alk/ros-1–rearranged nsclc
-
4:49
emerging alk/ros1 tkis for nsclc
-
4:05
the evolution of alk/ros1-targeted therapy in nsclc
-
4:43
upfront therapy for alk/ros1-rearranged nsclc
-
6:30
treatment options for alk/ros1 mutation
-
3:15
ros1 rearrangements in mnsclc
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
6:27
alk inhibitor sequencing in nsclc
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
2:12
dr. drilon on entrectinib in patients with ros1-positive nsclc
-
1:27
dr. ou on the use of crizotinib in patients with ros1-rearranged nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
1:05
dr. aggarwal on emerging treatment approaches in alk nsclc
-
4:55
ros1-rearranged nsclc
-
31:43
new ideas and new treatment options for acquired resistance for alk/ros1
-
18:41
extreme rare mutations in lung cancer (ros1, trk, her2): treatment opportunities
-
5:30
sequencing therapy in alk/ros1-rearranged nsclc
-
40:53
alk and ros1 in lung cancer next generation targeted therapies